Poster Topical Area: Aging and Chronic Disease

Location: Auditorium

Poster Board Number: 45

P01-025 - High dose of ω3 fatty acid supplementation for four weeks positively influences protein metabolism in Chronic Obstructive Pulmonary Disease

Sunday, Jun 10
8:00 AM – 6:00 PM

Objectives: Enhanced whole body protein turnover, which is an energy consuming process, is commonly observed in Chronic Obstructive Pulmonary Disease (COPD) and suggested to be related to the increased systemic inflammatory response in these patients. The fish oil eicosapentaenoic and docosahexaenoic acids (EPA+DHA) are ω3 fatty acids with anti-inflammatory properties. This study investigates whether 4 weeks of EPA and DHA supplementation is able to reverse the enhanced whole body protein turnover and reduce postabsorptive protein catabolism in COPD patients in a dose dependent way.


Methods: In 32 patients with moderate to severe COPD (GOLD stage II-IV) and 34 healthy controls, the stable isotopes of Phenylalanine (PHE)-[ring-2H5] and Tyrosine (TYR)-[13C9,15N] where administered intravenously via primed constant and continuous infusion to measure postabsorptive protein synthesis (PS) and breakdown (PB) and net protein catabolism (PB-PS). Each COPD subject received, according to a randomized, double-blind, three-group design, a daily dose of EPA+DHA (3.5g vs 2g EPA+DHA vs placebo) via gel capsules for 4-weeks. Whole body protein metabolism was assessed in all COPD subjects both pre- and post intervention. Plasma amino acid concentrations and enrichments were measured by LC-MS/MS and statistics by unpaired t-tests. Data are provided as mean ± SE.


Results: Postabsorptive PB was higher in the COPD than in the control group (66.6 ± 1.2 vs. 63.0 ± 1.4 umol/kg FFM*h, p=0.046) at baseline. Daily intake for 4 weeks of 3.5g of EPA+DHA but not 2g of EPA+DHA resulted in a reduction in postabsorptive protein turnover (difference high dose EPA+DHA vs. placebo: 5.52 ± 2.40 umol/kg FFM*h, p=0.026) and net protein catabolism (difference high dose EPA+DHA vs. placebo: 0.93 ± 0.38 umol/kg FFM*h, p=0.013) in the COPD group.


Conclusions: Daily intake of high dose of oral ω3 fatty acids for 4 weeks is able to reverse the enhanced postabsorptive whole body protein turnover and reduce net protein catabolism in Chronic Obstructive Pulmonary Disease.




Funding Source: R-01HL095903 from the National Heart, Lung and Blood Institute

CoAuthors: Renate Jonker, PhD – Texas A&M University; Sunday Simbo, PhD – Texas A&M University; Hooriya Sulaiman, MSc – Texas A&M University; Rajesh Harrykissoon, MD – College Station Medical Center; Anthony Zachria, DO – College Station Medical center; Eugene Veley, MD – Baylor Scott and White Medical Center; Nicolaas Deutz, MD, PhD – Texas A&M University

Marielle PKJ.. Engelen

Associate Professor
Texas A&M University
College Station, Texas